近日,礼来宣布FDA已批准Zepbound(tirzepatide)治疗肥胖人群的中度至重度阻塞性睡眠呼吸暂停(OSA)的新适应症。在使用Zepbound的同时,应减少热量饮食并增加体育锻炼。OSA适应症的获批,让礼来在与目前最强劲的对手诺和诺德的竞争中又添了一块重磅筹码。图片来源:摄图网拿下首个Obstructive sleep apnea(OSA),阻塞性睡眠呼吸暂停症,是睡眠状态下反复出现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.